ofatumumab
DrugOfatumumab in addition with ESHAP therapy
Other names: ARZERRA
NCT Number: NCT01195766
The aim of this study is to analyze the efficacy of O-ESHAP treatment for Hodgkin's lymphome patients that have a first line chemotherapy treatment failure due to refractoriness, partial response or relapsed.
In the same way, mortality, global survival and free-progression survival after O-ESHAP treatment and TAPH will also analyzed.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 2
Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
In addition to the above:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ofatumumab in addition with ESHAP therapy
Other names: ARZERRA
Time frame: 4 years follow-up
Time frame: 4 years follow-up
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Other
Phase II-study Using Ofatumumab and ESHAP Followed by Autologous Trasplant of Hemopoietic Precursors for the Treatment of Classic Hodgkin's Lymphoma on Relapse, Partial Response or Refractory to First Line Treatment
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01716806
Hematologic Diseases, Hemic and Lymphatic Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT00478959
Hemic and Lymphatic Diseases, Hodgkin Disease
View Trial DetailsNCT00062868
Disease Attributes, Hemic and Lymphatic Diseases
Houston, Texas, United States
View Trial DetailsNCT02389101
Hemic and Lymphatic Diseases, Hodgkin Disease
Turku, Finland
View Trial Details